Dorsey Wright & Associates Purchases 12,535 Shares of Medpace Holdings, Inc. $MEDP

Dorsey Wright & Associates boosted its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 126.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 22,420 shares of the company’s stock after acquiring an additional 12,535 shares during the period. Medpace comprises approximately 2.7% of Dorsey Wright & Associates’ holdings, making the stock its 6th biggest holding. Dorsey Wright & Associates owned 0.08% of Medpace worth $12,592,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Optiver Holding B.V. purchased a new stake in shares of Medpace in the third quarter valued at $27,000. Steigerwald Gordon & Koch Inc. purchased a new position in Medpace during the fourth quarter worth about $30,000. Elyxium Wealth LLC purchased a new position in Medpace during the fourth quarter worth about $30,000. Quarry LP acquired a new stake in Medpace in the 3rd quarter worth about $35,000. Finally, Core Wealth Advisors LLC acquired a new stake in Medpace in the 4th quarter worth about $47,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Trading Up 0.7%

Shares of Medpace stock opened at $460.20 on Friday. The business’s fifty day moving average price is $453.33 and its 200 day moving average price is $499.77. Medpace Holdings, Inc. has a twelve month low of $301.90 and a twelve month high of $628.92. The stock has a market capitalization of $13.14 billion, a P/E ratio of 28.93, a PEG ratio of 2.32 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping the consensus estimate of $3.74 by $0.54. The company had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm’s revenue was up 26.5% on a year-over-year basis. During the same period in the prior year, the firm posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, sell-side analysts predict that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Insider Activity

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This represents a 44.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 20.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on MEDP. Barclays lowered their price target on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a report on Friday, April 24th. Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Robert W. Baird lowered their target price on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a report on Friday, April 24th. BMO Capital Markets lowered their target price on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a report on Friday, April 24th. Finally, Royal Bank Of Canada dropped their price target on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Medpace presently has a consensus rating of “Hold” and an average price target of $467.08.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.